Case Report of a Successful Pregnancy in a Cystic Fibrosis Patient with The c.1521_1523delCTT/c.3718-2477C>t Genotypes.

The aim of this case report was to show the consequences of pregnancy in a cystic fibrosis (CF) patient with a rare mutation. We present a case of a patient with CF, pregnant for the second time, who gave birth to a healthy child. Her mutation status revealed the presence of relatively rare mutation c.3718-2477C>T that is associated with a milder phenotype of the disease. During pregnancy, her vital signs were within normal limits. She had no exacerbations after the third gestational month. Cystic fibrosis is the most common genetic disorder among Caucasians. Over the last few decades, the survival rate and the lifespan of patients with CF have increased progressively. This is why more affected women are choosing to become pregnant. Predictive factors for the pregnancy outcome are basal pulmonary function [measured by forced expiratory volume/1 second (FEV1)], nutritional status [measured by body mass index (BMI)], diabetes and bacterial colonization. The report of our case emphasizes the need for establishing the exact mutations in CF patients who plan to become pregnant in order to predict the possible outcomes of this specific period of life. Moreover, genetic counseling is strongly recommended for the right understanding of the pregnancy risks in such cases.

[Identification the risk of preterm labor :the role of fetal fibronectin].

UNLABELLED: Fibronectins represent a group of glycoproteins, which form "molecular glue" and are necessary in the interaction between a cell and a cell. The existence of fetal fibronectin in pregnant woman's vagina up to 22 g.w. is normal. In a normally proceeding pregnancy between 22 g.w. and 35 g.w. there is not supposed to be found fetal fibronectin in cervico-vaginal secretion. Its presence is a highly informative biological marker for the risk of premature birth. AIM: The aim of this research was to determine the risk for premature birth through applying fetal fibronectin test as a specific marker to pregnant women with or withthout symptoms of threatened birth. METHODS: A prospective longitudinal study has been carried out. The tests have been applied to hospitalized patients in University hospital "Majchin dom", Clinic of Pathologic pregnancy and Delivery room. Tests have been applied on 116 patients in totally). The pregnant have been separated in two groups depending on the fact of presence or absence of premature birth symptoms. The screening methods used were: the fFN test and the cervical length measurement by transvaginal according to an established protocol. CONCLUSION: From the total of 116 patients, in 78 we have received positive tests for fetal fibronectin; in 38 - negative test. With asymptomatic patients, having higher risk of preterm birth, the percent of positive tests has been lower (14%). With asymptomatic patients with higher percent of risk factors have been: short cervix (38%), multiple pregnancy (29%), followed by patients with diagnosis of preterm birth in the past (25%) and bleeding in earlier terms. Estimating positive and negative predictive rate, we have achieved following results: The test for fetal fibronectin has excellent predictive rate - 97%, which coincides with the great deal of research until this moment in the world. Referring to the positive predictive rate--it is not sufficient--only 19%.

[Saforelle - a new approach to treat vaginitis].

Infections of the vulva and vagina are one of the most common gynecological diseases. They can be determined by a variety of physical, chemical and biological factors. The main risk factors contributing to vaginitis are aerobic and anaerobic bacterias, fungal and viral infections, and irritants. Subjective complaints are pruritus, vulvar and/or perivulvar erytema and different in volume and characterization discharge. Excepting etiological treatment in most cases it is necessary to use additional agents, for example Saforelle.

[Tocolysis with nifedipin; its use in current practice].

AIM: The aim of the study is to establish the safety and efficacy of calcium channel blocker- Nifedipin as tocolytic agents. A wide range of tocolytics have been utilized for the management of preterm labor Calcium channel blockers, namely nifedipine, gained popularity as tocolytics due to the oral route of administration, availability of immediate- and slow-release preparations, the low incidence of maternal adverse effects associated with their use, and the fact that they are inexpensive. METHODS: 88 pregnant women in preterm labor participated in a prospective longitudinal study Inclusion criteria were: gestational age between 24 and 34 weeks gestation; uterine contractions in 10-15 min interval; single pregnancy, lack of contraindications for tocolysis. In all cases the calcium antagonist Nifedipine was used in dosage 4 x 10 mg per os. The clinical response to tocolysis, gestational age at delivery and potential side effects were analyzed. RESULTS: 91 pregnant women participated in the study. Three were excluded because they refused to participate. 88 pregnancies were finally analyzed. In nine of them maternal contractions persisted despite of treatment. The other 79 pregnancies were delayed 48 hours to receive antenatal corticosteroids. From all these 79 pregancies 66 delayed 7 days. The most common adverse effects were tachycardia, hypotonia, headache, dizziness, but they escape soon after the first dose. CONCLUSION: Nifedipine is an effective oral tocolytic with few maternal side effects.

[Perinatal mortality of IUGR neonates].

This study was conducted to evaluate the role of intrauterine fetal growth restriction (IUGR) in the perinatale mortality. A prospective study was designed, including 329 consecutive singleton pregnancies between 24 to 40 weeks' gestation, whose body weight is under 10th percentile for the gestational week. The control group consist of 530 appropriate for the gestational week (AGA) in the same period of gestation. The fetuses are without inborn malformations. The results show grater stillbirth rate in the group of hypotrophic than in the eutrophic neonates. In the group under 27th week of gestation is 2.6% forAGA and 8.3% for IUGR, for the group between 28-31 w.g. is 9.6% and 21.1% respectively and for 32-35 wg. is 2.3% against 13.1%. Perinatal mortality rate (stillbirth and demised before discharged) for the group before 27th w.g. is 65.8% for AGA and 72.2% for IUGR (P > 0.05). Between 28-31 w.g. is 28.4% and 50.0%, for 32-35 is 6.9% and 27.8% respectively (P > 0.01). After 37th w.g. perinatal mortality rate is less in AGA than in SGA fetuses. In conclusion the stillbirth rate is more frequent in IUGR fetuses than in AGA and frequencies is more pronounce in late preterm pregnancy. The fetal hypotrophy has deleterious effect on neonatal survival rate.

[Identification of preterm labor: the role of fetal fibronectin in parents with symptoms].

AIM: To determine whether the presence of fetal fibronectin in vaginal secretions of patients with symptoms suggestive of preterm labor predicts preterm delivery. Fetal fibronectin, a large molecular weight glycoprotein produced in the chorion, is expressed in cervical and vaginal secretions in women with disruption of the choriodecidual junction by labor or by inflammation. METHODS: A prospective observational longitudinal study from January 2013 till December 2013 was performed on patients between 24 and 32 weeks of gestation with symptoms of preterm labor, intact membranes, and cervical dilation < 4 cm (total patients = 86). The endpoint was the delivery at 34 weeks or more. The screening methods used were: the fFN test and the cervical length measurement by transvaginal according to an established protocol. CONCLUSION: The presence of FFN in vaginal or cervical secretions before 35 weeks is a is a strong predictor that preterm delivery is unlikely within the next 7 to 14 days. The predictive power of FFN is stronger at earlier gestation ages (24-29 wks) than it is later in pregnancy and is stronger for short-term prediction (7-14 d).

[Preterm birth in Bulgaria--changes in aetiology and incidence in the last decade].

There is no decrease in the incidence of preterm birth in Bulgaria and in the world, despite of all the therapeutic and prophylactic efforts. The rate of prematurity in University Maternity Hospital 'Maichin dom' in the last decade has increased significantly- from 11.6% in 2003 to 17.5% in 2013. The numbers are higher than the national average due to the essence of the Hospital being a leading clinical and scientific center. Thorough analysis demonstrates significant increase in the first grade prematurity being 5.8% of all live births in 2003 and 10.2% of all live births in 2013. In fact 58% of all premature births result in first grade preterm newborn. There is no significant increase in the forth grade- severe prematurity in the last decade. We believe that this increase in preterm birth rate is due to several reasons: the success of assisted reproductive technologies, which in Bulgaria leads to a significant increase in the number of multiple pregnancies; destructive/ablative methods of treatment of cervical intraepithelial neoplasia, especially LLETZ (LEEP), postponing of first pregnancy, increase in the number of adult primiparous women and as a whole pregnancy at later age, pregnancy in puberty. All these impose changes in the protocol for pregnancy follow up. Furthermore, we believe it is high time to increase the effectiveness of this service, as lack of adequate follow up is a reason for preterm birth on its own.

[Preterm birth--incidence and etiology].

Preterm birth is a major societal and economic problem. To him is accounting for 80 to 90% of neonatal morbidity and mortality worldwide. It is recognized as a complex multifactorial condition with different underlying etiologies. Paramount in the prevention of preterm birth is physician education regarding known risk factors, signs and symptoms of preterm labor and the role of close follow-up in the patients identified as high risk.

[HIV infection in pregnant women and risk of preterm birth].

According to estimates by WHO and UNAIDS, 34 million people were living with HIV at the end of 2011. Transmission of the human immunodeficiency virus (HIV) from mother to child can occur in utero, during labour or after delivery from breastfeeding. The majority of infants are infected during delivery. Clinical records have found more evidence of an increased rate of preterm delivery in HIV-positive women in low income countries.

[Six-month follow-up of the effect of neomenor in patients with painful menstruation].

Neomenor is herbal medication especially created to permanently relieve painful menstruation symptoms in girls and women with primary dysmenorrhea. It supplies the organism with substances essential for the metabolic processes that guarantee normal menstrual cycles. In some women these substances are out of balance, there is an excess of prostaglandins, which leads to painful periods, menstrual cramps and even migraine. Each NEOMENOR tablet contains 400 mg of standardized extracts from stalks of: Astragalus glycypyhyllos (Wild liquorice), Erodium cicutarium (Redstem Stork's Bill) and Geranium sanguineum (Bloody Cranesbill). Their biologically active substances inhibit the synthesis of prostaglandins and their secretion into the uterus, hence strong muscle contractions are reduced and menstrual cramps disappear. The aim of this short study is to gain personal impressions about the action of the preparation. We have tested 35 girls and women with middle-age--18.74 on (14-28 years) with menarche--average at 12.8, suffering of primary dysmenorrhea. We have watched following factors: degree of dysmenorrhea, duration of complaints, habitus, gynecological and mental status, used painkillers. As a result of three months treatment 63% of the patients with III-d and 37% with II-nd grade of dysmenorrhea transformed in 42% with II-nd and 45% with I-st grade of dysmenorrhea. Only in 4 patients (11%) therapy was without success. The monitoring continues.